Elotuzumab: the first available immunotherapeutic arrow against relapsed-refractory Multiple Myeloma. European Journal of Oncology and Environmental Health, [S. l.], v. 22, n. 2, p. 65–70, 2017. Disponível em: https://mattioli1885journals.com/index.php/EJOEH/article/view/6857.. Acesso em: 18 jul. 2024.